Rep. Gilbert Cisneros has disclosed a purchase of Artivion, Inc. Common Stock (AORT) under the STOCK Act, according to a Periodic Transaction Report filed with the U.S. House of Representatives. The transaction, executed by the member of Congress personally, was dated 2026-07-16 and valued between $1,001 and $15,000, a range that places it in the smaller tier of congressional stock disclosures.
The filing indicates the AORT shares are held through 150 Main Street Trust, with Bank of America listed as the custodial brokerage. This structure is typical of the intermediary arrangements members of Congress often use to hold and manage individual securities while in office. Our internal classification tags this filing as a ‘congress buy’ signal, reflecting a straightforward purchase transaction rather than a sale, exchange, or more complex financial instrument.
A Notable Cross-Signal at Artivion
What makes this disclosure worth tracking is its proximity to activity from inside Artivion itself. Company insider Holloway Jean F sold AORT shares on 2026-08-12, in a transaction valued at $27,835, falling within 30 days of Cisneros’s reported purchase date. Insider sales and congressional purchases moving in different directions around the same window don’t establish any coordinated action or wrongdoing, but they do create the kind of overlapping timeline that data-driven observers of Capitol Hill trading activity tend to flag for context.
STOCK Act disclosures like this one exist precisely so the public can see when lawmakers buy or sell individual stocks, and filing them is a legal obligation for members of Congress, not an indication of impropriety. Members are required to report transactions above a certain threshold within a set window after execution, and the dollar amounts are reported in broad ranges rather than exact figures, which is why this purchase appears as falling between $1,001 and $15,000 rather than a precise dollar amount.
Artivion, which trades on the Nasdaq under the ticker AORT, is a medical device company focused on cardiac and vascular surgery products. Congressional trading in small- and mid-cap healthcare names occasionally draws attention from data trackers simply because the sector intersects with legislation and regulatory activity that lawmakers themselves may vote on or oversee, though this filing on its own offers no indication of any such connection.
Readers interested in tracking how this position develops can watch for any subsequent disclosures tied to Cisneros’s AORT holding, as well as further insider transaction filings from Artivion executives, which are publicly available through standard SEC and House disclosure channels.